Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.
about
Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future TherapiesExploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell VaccinesSeverity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomasImmunotherapy advances for glioblastomaImmunotherapy for primary brain tumors: no longer a matter of privilegeDendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trialsAn update on vaccine therapy and other immunotherapeutic approaches for glioblastomaClinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysisDCVax®-L--developed by Northwest BiotherapeuticsImmune Checkpoint in Glioblastoma: Promising and ChallengingCytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients.Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.Dendritic cell immunotherapy in uterine cancer.Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma.The future of high-grade glioma: Where we are and where are we going.Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.Induction of antigen-specific cytotoxic T-cell response by dendritic cells generated from ecto-mesenchymal stem cells infected with an adenovirus containing the MAGE-D4a gene.Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma modelIrradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma.Glioma stem cells and immunotherapy for the treatment of malignant gliomas.Immunotherapy in glioblastoma: emerging options in precision medicinePrioritization schema for immunotherapy clinical trials in glioblastoma.Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma.Dendritic cell-based immunotherapy in ovarian cancer.Clinical trials in cellular immunotherapy for brain/CNS tumors.Myeloid-derived suppressor cells in glioma.Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives.Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.Vaccine-based immunotherapy for glioblastoma.Active dendritic cell immunotherapy for glioblastoma: Current status and challenges.Glioblastoma: molecular pathways, stem cells and therapeutic targets.Toward precision medicine in glioblastoma: the promise and the challenges.Brain Tumor Immunotherapy: What have We Learned so Far?Glioblastoma targeted therapy: updated approaches from recent biological insights.Vaccination strategies for neuro-oncology.Primary analysis for clinical efficacy of immunotherapy in patients with pancreatic cancer.Immunomonitoring in glioma immunotherapy: current status and future perspectives.
P2860
Q26752558-C792D754-E55B-41E8-96CD-CFAE70C796F4Q26772715-A31CA0BE-0BEB-49EA-BB9F-80167121F88AQ26862551-9BF0F1A5-91AA-4614-ABF7-E920AE4C2AF0Q26866513-12CDCA92-A775-423E-A69D-A31185F6E800Q27002510-6B79D93C-99F4-4AD1-A45B-155279A77E74Q27014829-DCA274CB-C88F-4422-B561-5C4EC4F98BC3Q27024830-05BD07B5-088D-490C-A9B8-486A496625FEQ27348437-4D9EDA02-BEBB-4F98-90F9-882335271B10Q30875456-07C57BF6-EDB1-4598-81C3-28F2CF20150FQ33650058-E6466018-851D-4300-B7DF-32B20447967CQ33691858-3624BCD8-C1C7-4C24-9D39-3392E4C899E1Q34276759-20D647BE-72A6-4EAC-80C3-28C2EBE64741Q34291122-5C23E927-8245-4932-A814-F478A3FB16C5Q34383339-A110CE71-F7F1-4866-AADC-EDE99FE8E876Q34523918-B869FF2D-A0BA-40A8-A65B-1E070205DEB2Q34533616-694146AE-51C6-4578-B25C-7E0A6BDB1BFEQ35114090-83963D1D-2E93-4E4E-86FF-5B2986E5B1E4Q35799695-C35728C0-8E7D-439A-8EB4-9273A456D5DDQ35988047-90F4FD30-8242-4A86-B6F8-837E3D0D04F5Q36224057-CE52B2C4-554A-4C4E-B762-E5A8113BABC5Q36514324-66CF5B46-5CAF-4F46-9139-CAA0D768A1B4Q36710917-57768B4C-8860-48D1-89FD-D6EBB9271D82Q36898699-34C2AF5C-EFDF-4150-B846-DF15D2866825Q37050960-576DE1FA-4E05-4907-BE56-3DB50098930CQ37078999-0AEEED07-CA41-431A-B74C-65641681427FQ37126620-8F4FE1CB-1889-4978-915E-C55E76C0B723Q37554417-D21F7912-8994-436A-B3A0-D0A5CDB2549DQ38094811-1048CBAB-A7CD-47D3-ABB4-8DE6871CBE03Q38161536-93067825-0430-42E9-9CCF-3276A2FFD7E4Q38176625-9C5E1787-D5AB-44C7-821A-A8423FF2667FQ38208388-F25355BC-90A5-4535-B4AF-EBA593B13CD2Q38233114-FDB6527D-5453-465A-A9B1-C0FC416613EDQ38301084-051FC94A-1801-4C6C-919A-545C4668BC22Q38393328-ECF9356A-527C-4943-8CD9-E9FB996C006AQ38454659-6C1FE9EA-4D4A-40E0-BAE2-F7CC58562E7FQ38542113-50BA9028-5EA5-4E7A-8601-3B916B08A452Q38597700-A1A5DED9-3CFE-4456-9197-49B958B63132Q38620079-9DEF77F4-C353-4039-B6C2-A4E85E7BDA14Q38632737-6DD26B59-C77C-40AC-9521-5067DD8DD094Q38659771-662AAC30-CA6C-4B0B-8C83-48310B058D01
P2860
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Integration of autologous dend ...... the HGG-2006 phase I/II trial.
@ast
Integration of autologous dend ...... the HGG-2006 phase I/II trial.
@en
Integration of autologous dend ...... the HGG-2006 phase I/II trial.
@nl
type
label
Integration of autologous dend ...... the HGG-2006 phase I/II trial.
@ast
Integration of autologous dend ...... the HGG-2006 phase I/II trial.
@en
Integration of autologous dend ...... the HGG-2006 phase I/II trial.
@nl
prefLabel
Integration of autologous dend ...... the HGG-2006 phase I/II trial.
@ast
Integration of autologous dend ...... the HGG-2006 phase I/II trial.
@en
Integration of autologous dend ...... the HGG-2006 phase I/II trial.
@nl
P2093
P2860
P921
P1476
Integration of autologous dend ...... the HGG-2006 phase I/II trial.
@en
P2093
Frank Van Calenbergh
Guido Wilms
Hilko Ardon
Jan Goffin
Johan Menten
Paul Clement
Philippe Demaerel
Stefaan W Van Gool
Steffen Fieuws
Steven De Vleeschouwer
P2860
P2888
P304
P356
10.1007/S00262-012-1261-1
P577
2012-04-22T00:00:00Z
P5875
P6179
1025417593